Eli Lilly ($LLY) CEO John Lechleiter says he's standing by his plans to invest big money into R&D, rather than cutting expenses to prepare for new generic competition. Lechleiter tells The Wall Street Journal that he sees "the light at the end of the tunnel," but if pipeline failures continue, then cuts would have to follow. Report